Latest & greatest articles for chronic kidney disease

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on chronic kidney disease or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on chronic kidney disease and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for chronic kidney disease

41. Improvements in Fatigue at Higher Achieved Hemoglobin Levels Among Chronic Kidney Disease Patients: A Systematic Review and Meta-Analysis Full Text available with Trip Pro

Improvements in Fatigue at Higher Achieved Hemoglobin Levels Among Chronic Kidney Disease Patients: A Systematic Review and Meta-Analysis Improvements in Fatigue at Higher Achieved Hemoglobin Levels Among Chronic Kidney Disease Patients: A Systematic Review and Meta-Analysis | Research Square Browse Tools & Services Your Cart See the published version of this article at . This is a preprint, a preliminary version of a manuscript that has not completed peer review at a journal. Research Square (...) does not conduct peer review prior to posting preprints. The posting of a preprint on this server should not be interpreted as an endorsement of its validity or suitability for dissemination as established information or for guiding clinical practice. Research article Improvements in Fatigue at Higher Achieved Hemoglobin Levels Among Chronic Kidney Disease Patients: A Systematic Review and Meta-Analysis Murilo Guedes, Camila R. Guetter, Lucas HO Erbano, Andre G. Palone, Jarcy Zee, Bruce M. Robinson

2020 Research Square

42. Management of Chronic Kidney Disease

Disease Guideline, July 2019 Clinical Problem and Management Issues Chronic kidney disease (CKD) is an increasingly common clinical problem that raises a patient’s risk for developing several life-threatening medical conditions, including end- stage renal disease (ESRD) and cardiovascular disease (CVD). Appropriate treatment can delay or prevent these adverse outcomes. However, CKD is often not recognized by clinicians or patients and as a result is often not optimally treated. Prevalence (...) indicating presence of abnormal kidney structure or function for 3 or more months can establish the diagnosis of CKD (Table 1). Ruling out acute (or acute on chronic) kidney injury involves clinical 13 UMHS Chronic Kidney Disease Guideline, July 2019 judgment in the clinical context of either estimated GFR (eGFR) 20% in eGFR, or an increase in serum creatinine = 0.3. During the initial evaluation of CKD, common causes and predisposing conditions for acutely decreased eGFR, including pre-renal and post

2020 University of Michigan Health System

43. Information Technology-based Interventions for Health Care Support in Patients with Chronic Kidney Disease: A Systematic Review Full Text available with Trip Pro

). Evaluating the prevalence and opportunity for technology use in chronic kidney disease patients: A cross-sectional study. BMC Nephrology, 19(1), 4–11. https://doi.org/10.1186/s12882-018-0830-8 Chiou, C. P., & Chung, Y. C. (2012). Effectiveness of multimedia interactive patient education on knowledge, uncertainty and decision-making in patients with end-stage renal disease. Journal of Clinical Nursing, 21(9–10), 1223–1231. https://doi.org/10.1111/j.1365-2702.2011.03793.x Cicolini, G., Simonetti, V (...) ., & Chang, P. (2014). Mockup design of personal health diary app for patients with chronic kidney disease. Studies in Health Technology and Informatics, 201, 124–132. https://doi.org/10.3233/978-1-61499-415-2-124 McGillicuddy, J. W., Gregoski, M. J., Weiland, A. K., Rock, R. A., Brunner-Jackson, B. M., Patel, S. K., … Treiber, F. A. (2013). Mobile Health Medication Adherence and Blood Pressure Control in Renal Transplant Recipients: A Proof-of-Concept Randomized Controlled Trial. JMIR Research Protocols

2020 Jurnal Ners

44. Efficacy and Safety of Mineralocorticoid Receptor Antagonists in Patients With Heart Failure and Chronic Kidney Disease

in HF patients and chronic kidney disease (CKD) with estimated glomerular filtration rate (eGFR) <60 mL/min/1.73 m 2 . We conducted a systematic review evaluating the efficacy and safety of MRA in patients with HF and CKD. PubMed, Embase, and Cochrane Central databases were searched for relevant studies on patients with HF and reduced renal function (defined as eGFR <60 mL/min/1.73 m 2 ). Seven studies with 5,522 patients were included. We found 3 studies in patients with HFrEF, 1 study with HFpEF (...) Efficacy and Safety of Mineralocorticoid Receptor Antagonists in Patients With Heart Failure and Chronic Kidney Disease Efficacy and Safety of Mineralocorticoid Receptor Antagonists in Patients With Heart Failure and Chronic Kidney Disease - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Welcome to the new PubMed. For legacy PubMed go to . Clipboard, Search History, and several other advanced features are temporarily

2020 EvidenceUpdates

45. COVID-19 rapid guideline: chronic kidney disease

Patients known or suspected to have COVID-19 8 3 Managing chronic kidney disease (CKD) 9 Modifying usual care 9 Medicines 9 Monitoring CKD 10 4 Specialist services 11 Referrals to renal services 11 Renal ultrasound 11 Hospital admission 12 5 Advanced chronic kidney disease 13 6 Healthcare workers 14 COVID-19 rapid guideline: chronic kidney disease (NG176) © NICE 2020. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and- conditions#notice-of-rights). Page 3 of 14Overview (...) . Be aware that there is no evidence from clinical or epidemiological studies that ACE inhibitors or angiotensin receptor blockers might worsen COVID-19. See: • the Renal Association UK position statement on COVID-19 and ACE inhibitor/ angiotensin receptor blocker use COVID-19 rapid guideline: chronic kidney disease (NG176) © NICE 2020. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and- conditions#notice-of-rights). Page 9 of 14• the Renal Association guidance

2020 National Institute for Health and Clinical Excellence - Clinical Guidelines

46. Chronic kidney disease: When should I suspect chronic kidney disease?

publication KDIGO 2012 Clinical practice guideline for the evaluation and management of chronic kidney disease [ ], and expert opinion in review articles on CKD [ ; ; ; ]. Investigating people with risk factors for CKD The aim of early identification and treatment of CKD is to decrease the risk of cardiovascular disease, progression to end-stage renal disease (ESRD), and mortality. The recommendation to investigate people with risk factors for CKD is based on the NICE clinical guideline [ ] and expert (...) Chronic kidney disease: When should I suspect chronic kidney disease? Diagnosis | Diagnosis | Chronic kidney disease | CKS | NICE Search CKS… Menu Diagnosis Chronic kidney disease: When should I suspect chronic kidney disease? Last revised in May 2020 When should I suspect chronic kidney disease? Arrange to assess for chronic kidney disease (CKD) in people with: for CKD. An incidental finding of: Raised serum creatinine and/or a serum estimated glomerular filtration rate (eGFR) of less than 60

2020 NICE Clinical Knowledge Summaries

47. Chronic kidney disease: What initial investigations should I arrange?

. Note: a significant reduction in serum creatinine, for example by more than 20%, may indicate significant renal impairment, in the presence of normal eGFR readings. Based on: [ ; ] Basis for recommendation The recommendations on initial investigations are based on the National Institute for Health and Care Excellence (NICE) clinical guidelines Chronic kidney disease. Early identification and management of chronic kidney disease in adults in primary and secondary care [ ] and Suspected cancer (...) Chronic kidney disease: What initial investigations should I arrange? Initial investigations | Diagnosis | Chronic kidney disease | CKS | NICE Search CKS… Menu Initial investigations Chronic kidney disease: What initial investigations should I arrange? Last revised in May 2020 What initial investigations should I arrange? If a diagnosis of chronic kidney disease (CKD) is , arrange initial investigations in primary care. Arrange blood tests for serum creatinine and estimated glomerular

2020 NICE Clinical Knowledge Summaries

48. Chronic kidney disease: Scenario: COVID-19

Chronic kidney disease: Scenario: COVID-19 Scenario: COVID-19 | Management | Chronic kidney disease | CKS | NICE Search CKS… Menu Scenario: COVID-19 Chronic kidney disease: Scenario: COVID-19 Last revised in May 2020 Scenario: COVID-19 From age 18 years onwards. How should my management vary when considering the possibility of COVID-19? In people with chronic kidney disease (CKD) and in the presence of the COVID-19 pandemic, National Institute of Health and Care Excellence (NICE) has made (...) when they should seek help and who to contact. Referrals to renal services To minimize risk from COVID‑19, NICE advises that clinicians should delay referral if the clinical need is not urgent, for example, if the person has mild-to-moderate proteinuria and a stable eGFR (including people with suspected inherited kidney disease). Continue to refer people for urgent outpatient appointments if there is a clinical need, for example, if the person has accelerated progression of CKD, which is defined

2020 NICE Clinical Knowledge Summaries

49. Chronic kidney disease: How should I assess suspected chronic kidney disease?

Chronic kidney disease: How should I assess suspected chronic kidney disease? Assessment | Diagnosis | Chronic kidney disease | CKS | NICE Search CKS… Menu Assessment Chronic kidney disease: How should I assess suspected chronic kidney disease? Last revised in May 2020 How should I assess suspected chronic kidney disease? If a diagnosis of chronic kidney disease (CKD) is , assess the person for possible associated clinical features. Ask about: General symptoms, such as lethargy, itch (...) , breathlessness, cramps (often worse at night), sleep disturbance, bone pain, or loss of appetite, vomiting, weight loss, and taste disturbance (often present with end-stage disease). Urine output, such as polyuria (tubular concentrating ability is impaired); oliguria; nocturia (due to impaired solute diuresis or oedema); or anuria (due to possible acute kidney injury [AKI], obstructive uropathy causing urinary retention; or end-stage renal disease). Any potentially , including over-the-counter or herbal

2020 NICE Clinical Knowledge Summaries

50. Chronic kidney disease: ACE-inhibitors and AIIRAs

Chronic kidney disease: ACE-inhibitors and AIIRAs ACE-inhibitors and AIIRAs | Prescribing information | Chronic kidney disease | CKS | NICE Search CKS… Menu ACE-inhibitors and AIIRAs Chronic kidney disease: ACE-inhibitors and AIIRAs Last revised in May 2020 ACE-inhibitors and AIIRAs Contraindications and cautions Use of angiotensin-converting enzyme (ACE) inhibitors is contraindicated in people: With a history of angio-oedema associated with previous exposure to an ACE-inhibitor (...) -dose diuretics may result in volume depletion and a risk of hypotension. Lithium — reversible increases in serum lithium concentrations and toxicity have been reported during concomitant administration. Monitoring of serum lithium levels is recommended. NSAIDs — attenuation of antihypertensive effect may occur and there may be an increased risk of deteriorating renal function, including possible acute kidney injury and hyperkalaemia. Consider monitoring renal function after starting concomitant

2020 NICE Clinical Knowledge Summaries

51. Chronic kidney disease

anaemia, renal mineral and bone disorder, end-stage renal disease (ESRD), and increased all-cause mortality. CKD should be suspected in people with: Risk factors for CKD. An incidental finding of raised serum creatinine and/or eGFR of less than 60 mL/min/1.73 m 2 ; or markers of kidney damage. Possible clinical features of CKD (rare unless end-stage disease). If a diagnosis of CKD is suspected, initial investigations should be arranged and repeated as appropriate: Serum creatinine and eGFR. Early (...) Chronic kidney disease Chronic kidney disease | Topics A to Z | CKS | NICE Search CKS… Menu Chronic kidney disease Chronic kidney disease Last revised in May 2020 Chronic kidney disease (CKD) is an abnormality of kidney function or structure that is present for more than 3 months, with implications for health Diagnosis Management Prescribing information Background information Chronic kidney disease: Summary Chronic kidney disease (CKD) is a reduction in kidney function or structural damage

2020 NICE Clinical Knowledge Summaries

52. Chronic kidney disease: Scenario: Management of chronic kidney disease

, and treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD) [ ]; and expert opinion in review articles on chronic kidney disease (CKD) [ ; ; ; ]. Monitoring estimated glomerular filtration rate (eGFR) and urinary albumin:creatinine ratio (ACR) to identify disease progression Early detection of disease progression can allow for timely preparation for renal replacement therapy, if indicated, for people with CKD stage 4 before progression to stage 5 disease [ ]. People with a declining (...) , phosphate, calorie and salt intake; and end-stage renal disease (ESRD) may require renal replacement therapy (haemodialysis/peritoneal dialysis or eventual kidney transplantation). Renal anaemia may include treatment with erythropoiesis-stimulating agents, and possible intravenous iron if there is associated refractory iron deficiency. Renal mineral and bone disorder may involve phosphate dietary restriction, use of phosphate binders, and specialist endocrinology input. Persistent metabolic acidosis may

2020 NICE Clinical Knowledge Summaries

53. The Association Between Chronic Kidney Disease and New Onset Renal Replacement Therapy on the Outcome of COVID-19 Patients: A Meta-analysis Full Text available with Trip Pro

information view the page. Please read and accept the and check the box to generate a sharing link. I have read and accept the terms and conditions Share URL copied to clipboard View permissions information for this article The Association Between Chronic Kidney Disease and New Onset Renal Replacement Therapy on the Outcome of COVID-19 Patients: A Meta-analysis .entryAuthor" data-author-container-selector=".NLM_contrib-group"> Show all authors 1 Faculty of Medicine, Universitas Pelita Harapan, Tangerang (...) ). Abbreviations: ARDS: acute respiratory distress syndrome; CKD: chronic kidney disease; COVID-19: Coronavirus Disease 2019; IC: intensive care. Renal replacement therapy and poor outcome in COVID-19 The new onset RRT was associated with increased composite poor outcome (RR 18.04 [4.44, 73.25], P < .001; I 2 : 87%, P < .001). Subgroup analysis also showed significantly increased risk for mortality (RR 26.02 [5.01, 135.13], P < .001; I 2 : 60%, P = .06), severe COVID-19 (RR 12.95 [1.93, 86.82], P = .008; I 2

2020 Clinical Medicine Insights: Circulatory, Respiratory and Pulmonary Medicine

54. Elevated Osteoprotegerin Concentration Predicts Increased Risk of Cardiovascular Mortality in Patients with Chronic Kidney Disease: A Systematic Review and Meta-Analysis Full Text available with Trip Pro

in patients with chronic kidney disease (CKD), and these patients have a 10–30 times higher cardiovascular mortality risk than the general population [ ]. In addition to the classic tetrad of smoking, diabetes, dyslipidaemia, and hypertension, mineral and bone metabolism disorders are also identified as risk factors for cardiovascular mortality in patients with CKD [ - ]. Osteoprotegerin (OPG) is a secretory glycoprotein of the TNF receptor superfamily [ ] and has been reported to be involved in bone (...) the literature search. Q.H., J.L., and F.H. selected the included studies. N.H. and X.H. extracted data from each included study. F.H. and Y.L. assessed the study quality. Q.H. prepared the tables and all figures. F.H. supervised the study and acted as an arbitrator for all possible disagreements. All authors read and approved the content. Related Articles: References Foley RN, Parfrey PS, Sarnak MJ. Clinical epidemiology of cardiovascular disease in chronic renal disease. Am J Kidney Dis. 1998 Nov;32(5

2020 Kidney and Blood Pressure Research

55. A network meta-analysis on comparative efficacy of statins focusing for prevention of contrast-induced acute kidney injury in chronic kidney disease patients undergoing percutaneus coronary intervention Full Text available with Trip Pro

mellitus and concomitant chronic kidney disease. Med J Chin PLA. 2014;39(1): 546-552 Patti G, Ricottini E, Nusca A, Colonna G, Pasceri V, D’Ambrosio A, et al. Short-term, high-dose atorvastatin pretreatment to prevent contrast-induced nephropathy in patients with acute coronary syndromes undergoing percutaneous coronary intervention (from the ARMYDA-CIN [atorvastatin for reduction of myocardial damage during angioplasty–contrast-induced nephropathy] trial. Am J Cardiol. 2011;108(1):1–7 Quintavalle C (...) , Fiore D, De Micco F, Visconti G, Focaccio A, Golia B, et al. Impact of a high loading dose of atorvastatin on contrast-induced acute kidney injury. Circulation. 2012;126(25):3008–16. Toso A, Maioli M, Leoncini M, Gallopin M, Tedeschi D, Micheletti C, Manzone C, Amato M, Bellandi F. Usefulness of Atorvastatin (80 mg) in Prevention of Contrast-Induced Nephropathy in Patients With Chronic Renal Disease. The American Journal of Cardiology. 20013;105(3):288-292. Abaci O, Arat Ozkan A, Kocas C, Cetinkal G

2019 Bali Medical Journal

56. Association of Baclofen With Encephalopathy in Patients With Chronic Kidney Disease. Full Text available with Trip Pro

Association of Baclofen With Encephalopathy in Patients With Chronic Kidney Disease. At least 30 case reports have linked the muscle relaxant baclofen to encephalopathy in patients with chronic kidney disease (CKD).To compare the 30-day risk of encephalopathy in patients with CKD and newly prescribed baclofen at greater than or equal to 20 mg per day vs less than 20 mg per day. The secondary objective was to compare the risk of encephalopathy in baclofen users vs nonusers.Retrospective

2019 JAMA

57. Development of Risk Prediction Equations for Incident Chronic Kidney Disease. Full Text available with Trip Pro

Development of Risk Prediction Equations for Incident Chronic Kidney Disease. Early identification of individuals at elevated risk of developing chronic kidney disease (CKD) could improve clinical care through enhanced surveillance and better management of underlying health conditions.To develop assessment tools to identify individuals at increased risk of CKD, defined by reduced estimated glomerular filtration rate (eGFR).Individual-level data analysis of 34 multinational cohorts from the CKD (...) %) had a slope of observed to predicted risk between 0.80 and 1.25. Discrimination was similar in 18 study populations in 9 external validation cohorts; calibration showed that 16 of 18 (89%) had a slope of observed to predicted risk between 0.80 and 1.25.Equations for predicting risk of incident chronic kidney disease developed from more than 5 million individuals from 34 multinational cohorts demonstrated high discrimination and variable calibration in diverse populations. Further study is needed

2019 JAMA

58. Cases in Precision Medicine: APOL1 and Genetic Testing in the Evaluation of Chronic Kidney Disease and Potential Transplant. Full Text available with Trip Pro

Cases in Precision Medicine: APOL1 and Genetic Testing in the Evaluation of Chronic Kidney Disease and Potential Transplant. This article discusses potential indications for genetic testing in an African American patient with chronic kidney disease who is being evaluated for a kidney transplant. Two known risk variants in the APOL1 (apolipoprotein L1) gene predispose to kidney disease and are found almost exclusively in persons of African ancestry. APOL1 risk variants are considered, including (...) whether clinicians should incorporate genetic testing in the screening process for living kidney donors. In addition to APOL1 testing, the role of diagnostic exome sequencing in evaluating potential transplant recipients and donors with a positive family history of kidney disease is discussed.

2019 Annals of Internal Medicine

59. Chronic Kidney Disease Diagnosis and Management: A Review. Full Text available with Trip Pro

Chronic Kidney Disease Diagnosis and Management: A Review. Chronic kidney disease (CKD) is the 16th leading cause of years of life lost worldwide. Appropriate screening, diagnosis, and management by primary care clinicians are necessary to prevent adverse CKD-associated outcomes, including cardiovascular disease, end-stage kidney disease, and death.Defined as a persistent abnormality in kidney structure or function (eg, glomerular filtration rate [GFR] <60 mL/min/1.73 m2 or albuminuria ≥30 mg (...) per 24 hours) for more than 3 months, CKD affects 8% to 16% of the population worldwide. In developed countries, CKD is most commonly attributed to diabetes and hypertension. However, less than 5% of patients with early CKD report awareness of their disease. Among individuals diagnosed as having CKD, staging and new risk assessment tools that incorporate GFR and albuminuria can help guide treatment, monitoring, and referral strategies. Optimal management of CKD includes cardiovascular risk

2019 JAMA

60. Dietary Priority Screening for Chronic Kidney Disease: Clinical Effectiveness and Guidelines

Dietary Priority Screening for Chronic Kidney Disease: Clinical Effectiveness and Guidelines Dietary Priority Screening for Chronic Kidney Disease: Clinical Effectiveness and Guidelines | CADTH.ca Find the information you need Dietary Priority Screening for Chronic Kidney Disease: Clinical Effectiveness and Guidelines Dietary Priority Screening for Chronic Kidney Disease: Clinical Effectiveness and Guidelines Last updated: January 14, 2019 Project Number: RB1297-000 Product Line: Research Type (...) : Devices and Systems Report Type: Summary of Abstracts Result type: Report Question What is the clinical effectiveness of dietary/nutrition priority screening tools for in-patients and outpatients with chronic kidney disease? What are the evidence-based guidelines for the use of dietary/nutrition prioritization tools for the delivery of nutritional therapy in the chronic kidney disease setting? Key Message One non-randomized study and three evidence based guidelines were identified regarding the use

2019 Canadian Agency for Drugs and Technologies in Health - Rapid Review